Company intelligence / Profile preview

OmegaBrite

Waltham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

OmegaBrite is a health and wellness company specializing in high-potency, pharmaceutical-grade Omega-3 fatty acid supplements. Founded by Dr. Carol Locke of Harvard Medical School, the company focuses on providing high-EPA formulations designed to support cardiac health, emotional well-being, and joint health. Their products are developed based on clinical research and are widely recognized for their purity and concentration. OmegaBrite's flagship product is a 70% EPA formulation, which has been used in numerous clinical trials. The company operates primarily in the direct-to-consumer and professional recommendation markets.

Therapeutic areas: PsychiatryImmunologyNeurologyMetabolic Disorders
Modalities: Small molecule
Industry: Food & Nutrition

Beyond the preview

Go deeper on OmegaBrite.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OmegaBrite.

Explore the full profile